Navigation Links
Qualitest Receives FDA Approval for Emoquette™ (.15 mg Desogestrel and .03 mg Ethinyl Estradiol), an Oral Contraceptive for Prevention of Pregnancy
Date:3/4/2011

HUNTSVILLE, Ala., March 4, 2011 /PRNewswire/ -- Qualitest Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Emoquette™ (Desogestrel and Ethinyl Estradiol Tablets. 0.15mg/0.03mg, generic Ortho-Cept®) for the prevention of pregnancy in women who elect to use oral contraceptives for the prevention of pregnancy.

About Qualitest

Founded in 1983, Qualitest provides affordable, high-quality generic pharmaceuticals. Featuring a current portfolio exceeding 600 products, the company has grown significantly since its inception and is now ranked in the top ten among all suppliers of generics, based on total prescriptions filled. Qualitest is a wholly owned subsidiary of Endo Pharmaceuticals (Nasdaq: ENDP), a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics (www.endo.com).  

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, the business combination between Endo and Qualitest, Endo's and Qualitest's financial position, results of operations, market position, product development and business strategy, as well as estimates of Endo's future total revenues, future expenses, future net income and future earnings per share.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may" "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the  business combination of the companies, future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the operations of Endo and Qualitest will not be integrated successfully; Endo's ability to successfully develop, commercialize and market new products; timing and results of pre-clinical or clinical trials on new products; Endo's and Qualitest's ability to obtain regulatory approval of any of their respective pipeline products; competition for the business of Endo's and Qualitest's branded and generic products, and in connection with its acquisition of rights to intellectual property assets; market acceptance of our future products; government regulation of the pharmaceutical industry;  Endo's dependence on a small number of products; Endo's dependence on outside manufacturers for the manufacture of a majority of its products;  Endo's dependence on third parties to supply raw materials and to provide services for certain core aspects of its business; new regulatory action or lawsuits relating to Endo's or Qualitest's use of narcotics in many of its core products; Endo's and Qualitest's exposure to product liability claims, market withdrawals and product recalls and the possibility that Endo may not be able to adequately insure itself; the successful efforts of manufacturers of branded pharmaceuticals to use litigation and legislative and regulatory efforts to limit the use of generics and certain other products; Endo's ability to successfully implement its acquisition and in-licensing strategy; regulatory or other limits on the availability of controlled substances that constitute the active ingredients of some of its products and products in development; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by third parties or the government, and the performance of indemnitors with respect to claims for which we have been indemnified; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of its total revenues; a determination by a regulatory agency that Endo is engaging or has engaged in inappropriate sales or marketing activities, including promoting the "off-label" use of its products, the risk that demand for and acceptance of our products or services may be reduced; the risk of changes in governmental regulations; the impact of economic conditions; the impact of competition and pricing and other risks and uncertainties, including those detailed from time to time in Endo's periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "RISK FACTORS" in our periodic and current reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Qualitest Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Qualitest Pharmaceuticals Issues Voluntary, Nationwide Recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg / 500 mg, NDC 0603-3888-20, 60 Count, Lot Numbers T150G10B, T120J10E and T023M10A and Phenobarbital Tablets, USP 32.4 mg, ND
2. Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management
3. Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
4. Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy
5. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
6. Nile Therapeutics Receives Positive NASDAQ Panel Decision
7. Echo Therapeutics Receives Frost & Sullivans 2011 Technology Innovation Award
8. Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog®
9. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
10. Mylan Receives Approval for Generic Version of Neurontin® Capsules
11. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 Pharmaceutical giant Johnson & ... a woman who says its talc-based powder products caused ... Ristesund $5 million in compensatory damages and $50 ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This is the ... In February, the same court awarded $72 million to ...
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/2/2016)... , May 2, 2016  While nearly three-quarters ... osteoporosis can have on their health, only about half ... according to the results of a new survey announced ... mark the start of National Osteoporosis Month, Hologic is ... which affects nearly 56 million Americans. Osteoporosis ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge , ... tooth removal, a common dental procedure, is performed for many adolescents and young adults ... in risks of complications. By providing wisdom tooth removal surgery at their office, Dr. ...
(Date:5/4/2016)... ... 04, 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega ... This synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg ... glutathione and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a ...
(Date:5/4/2016)... ... ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car rental ... at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses and ... as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 in ...
(Date:5/4/2016)... ... May 04, 2016 , ... Pharmacy Times , ... it was chosen as the Pharmaceutical News Provider of the Year in the ... the hard work and dedication of community members who strive to make the ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... small and compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and ... NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 batteries to produce ...
Breaking Medicine News(10 mins):